Although targeted tFNA-encapsulated curcumin effectively alleviated lipid-mediated liver injury in NAFLD mice, no significant differences were observed between targeted and non–targeted administrations in reducing plasma alanine transaminase (ALT) and aspartate transaminase (AST) activities. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.